Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.

In IHC-defined luminal A-like subtype patients, elafin-positive cells were prognostic of a highly significant reduction in RFS compared to elafin-negative tumors (Figure 4 B).

also in 132,142 other papers